RxDoctor Payments Data

Jose Abdenur

Clinical Biochemical Genetics · Orange, CANPI 1154428027

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,400 of the $6,567 with a category attached, or 97.5%. Ultragenyx Pharmaceutical Inc. accounts for 99.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $6,506 and has fallen 99.2% since, to $49 in 2021.

$6,567in general payments, 2019–2025

Across 13 payments — averaging $505.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ultragenyx Pharmaceutical Inc.$7K
  • Travere Therapeutics, Inc.$27
  • Alnylam Pharmaceuticals Inc.$19
$594,088in research payments, 2019–2025

Across 57 payments — averaging $10,423 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ultragenyx Pharmaceutical Inc.$576K
  • Saol International Limited$19K

What the payments were for

  • Consulting fees$6,40097%
  • Education$1673%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical biochemical genetics providers in Californiato place this figure against a meaningful peer group, so we don't.

Other clinical biochemical genetics in Orange

Where these figures come from

Is this you, or does something look wrong? →